Indywidualna Specjalistyczna Praktyka Lekarska Włodzimierz Kuś

This therapeutic area concentrates on heart‑related conditions, notably heart failure. The studies are designed to evaluate new treatment combinations that could lower the risk of cardiovascular death and reduce hospital admissions.

• Combination therapy with vicadrostat and empagliflozin
• Assessment of time to first cardiovascular death, hospitalization for heart failure, or urgent visit
• Focus on patients with preserved ejection fraction (LVEF ≥40%)

At Indywidualna Specjalistyczna Praktyka Lekarska Włodzimierz Kuś, investigators are testing innovative approaches to improve outcomes for individuals living with heart failure.

This field addresses disorders of lipid metabolism, especially hypertriglyceridemia and its severe variant. Trials aim to demonstrate the effectiveness and long‑term safety of an RNA‑based therapy that lowers fasting serum triglyceride levels.

• Plozasiran efficacy in reducing fasting triglycerides
• Long‑term safety evaluation in patients with hypertriglyceridemia
• Study of both moderate and severe hypertriglyceridemia populations

The site’s focused research provides hope for patients struggling with elevated triglyceride levels and seeks to expand therapeutic options in metabolic disease management.